Advertisement
Advertisement

GALT

GALT logo

Galectin Therapeutics Inc.

4.17
USD
Sponsored
+0.25
+6.35%
Jun 25, 11:20 UTC -4
Open

GALT Earnings Reports

Positive Surprise Ratio

GALT beat 30 of 42 last estimates.

71%

Next Report

Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/
-$0.09
Implied change from Q1 26 (Revenue/ EPS)
--
/
+12.50%
Implied change from Q2 25 (Revenue/ EPS)
--
/
-25.00%

Galectin Therapeutics Inc. earnings per share and revenue

On May 15, 2026, GALT reported earnings of -0.08 USD per share (EPS) for Q1 26, missing the estimate of -0.06 USD, resulting in a -30.72% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.66% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.09 USD, with revenue projected to reach -- USD, implying an increase of 12.50% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
For Q1 2026, Galectin Therapeutics Inc. reported EPS of -$0.08, missing estimates by -30.72%, and revenue of $0.00, 0% as expectations.
The stock price moved down -7.66%, changed from $2.35 before the earnings release to $2.17 the day after.
The next earning report is scheduled for Aug 12, 2026.
Based on -- analysts, Galectin Therapeutics Inc. is expected to report EPS of -$0.09 and revenue of -- for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement